Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Beneish M-Score : 0.00 (As of May. 28, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Reviva Pharmaceuticals Holdings's Beneish M-Score or its related term are showing as below:

During the past 5 years, the highest Beneish M-Score of Reviva Pharmaceuticals Holdings was 0.00. The lowest was 0.00. And the median was 0.00.

Reviva Pharmaceuticals Holdings Beneish M-Score Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings Beneish M-Score Chart

Reviva Pharmaceuticals Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Reviva Pharmaceuticals Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beneish M-Score	Get a 7-Day Free Trial													-	-	-	-	-

Competitive Comparison of Reviva Pharmaceuticals Holdings's Beneish M-Score

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Beneish M-Score falls into.

Reviva Pharmaceuticals Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Reviva Pharmaceuticals Holdings for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Mar24) TTM:

Last Year (Mar23) TTM:

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $13.50 Mil.
Total Assets was $13.50 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $8.72 Mil.
Total Current Liabilities was $14.49 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -7.434 + -9.724 + -10.491 + -12.443 = $-40.09 Mil.
Non Operating Income was 0.326 + 0.082 + 0.144 + -0.456 = $0.10 Mil.
Cash Flow from Operations was -11.726 + -8.876 + -6.179 + -5.317 = $-32.10 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $12.90 Mil.
Total Assets was $12.90 Mil.
Property, Plant and Equipment(Net PPE) was $0.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.00 Mil.
Selling, General, & Admin. Expense(SGA) was $5.24 Mil.
Total Current Liabilities was $6.56 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (13.497 + 0) / 13.497)	/	(1 - (12.902 + 0) / 12.902)
	=	0	/	0
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0 / (0 + 0))	/	(0 / (0 + 0))
	=		/
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(8.721 / 0)	/	(5.24 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0 + 14.492) / 13.497)	/	((0 + 6.56) / 12.902)
	=	1.07372	/	0.508448
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-40.092 - 0.096	-	-32.098)	/	13.497
	=	-0.599392

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Reviva Pharmaceuticals Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014

Website

https://www.revivapharma.com

Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.

Executives

Purav Patel	director	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu	officer: Chief Financial Officer	19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p.	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp	10 percent owner	250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena	director, 10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc	director, 10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat	director, 10 percent owner, officer: President and CEO	19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon	officer: Chief Medical Officer	19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin	director	19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc	10 percent owner	250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019